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 
    Abstract--Anaphylaxis is an increasingly prevalent life-
threatening allergic condition that requires people with 
anaphylaxis and their caregivers to be trained in the avoidance of 
allergen triggers and in the administration of adrenaline auto-
injectors. The prompt and correct administration of auto-
injectors in the event of an anaphylactic reaction is a significant 
challenge in the management of anaphylaxis. Unfortunately, 
many people do not know how to use auto-injectors and either 
fail to use them or fail to use them correctly. This is due in part to 
deficiencies in training and also to the lack of a system 
encouraging continuous practice with feedback. Assistive 
smartphone healthcare technologies have demonstrated potential 
to support the management of chronic conditions such as 
diabetes and cardiovascular disease, but there have been 
deficiencies in their evaluation and there has been a lack of 
application to anaphylaxis. This paper describes AllergiSense, a 
smartphone app and sensing system for anaphylaxis 
management, and presents the results of a randomized, 
controlled, pre-post evaluation of AllergiSense injection training 
and feedback tools with healthy participants. Participants whose 
training was supplemented with AllergiSense injection feedback 
achieved significantly better practiced injections with 90.5% 
performing correct injections compared to only 28.6% in the 
paper-only control group. In addition, the results provide 
insights into possible self-efficacy failings in traditional training 
and the benefits of embedding self-efficacy theory into the 
technology design process.  
 
Index Terms--Assistive Technology, Pervasive Healthcare, 
Anaphylaxis Management, Smartphone Wireless Sensing, Self-
Efficacy, Self-Management. 
I.  INTRODUCTION 
NAPHYLAXIS is a serious allergic reaction that is rapid 
in onset and can cause death [1, p. 392]. Its prevalence 
has dramatically increased in recent years [2] with an 
                                                         
This paper was submitted for review on June 11th 2015. This research was 
supported by the University of Birmingham UK, the Mexican Council of 
Science and Technology (Conacyt) and the Mexican Secretariat of Public 
Education (SEP). This study was funded by The Anaphylaxis Campaign UK's 
Small Grant Scheme (04-13-LHM) and approved by the University of 
Birmingham Ethics Committee (ERN_13-1496).   
L. U. Hernandez-Munoz is with Birmingham City University at 
Millennium Point, Curzon Street, Birmingham, B4 7XG. (Correspondence              
e-mail: Luis.Hernandez-Munoz@bcu.ac.uk). 
S. I. Woolley, T. Collins and L. Diwakar are with The University of 
Birmingham. D. Luyt, G. Stiefel and K. Kirk are with the University Hospitals 
of Leicester NHS Trust. N. Makwana is with Sandwell and West Birmingham 
Hospitals NHS Trust. C. Melchior is with Heart of England NHS Foundation 
Trust, T. C. Dawson is with the Worcestershire Acute Hospitals NHS Trust 
and G. Wong and L. Diwakar are with the University Hospitals Birmingham 
NHS Foundation Trust. 
 
estimated lifetime prevalence of 0.05-2% [3]-[5]. 
Anaphylactic reactions can occur rapidly after ingestion, 
inhalation or contact with an allergen that may be a food, 
prescription drug, insect sting, or a substance such as latex [6]. 
Foods are the most common allergens for children, 
adolescents and young adults while non-food allergens are 
more common for older adults [7]. Children frequently 
develop tolerance to milk, egg, soy and wheat allergens by 
school age, however, allergies to nuts and shellfish are more 
likely to be lifelong [8].  
   
     The first-line treatment for an anaphylactic reaction is the 
immediate administration of adrenaline (epinephrine) given 
via a pre-loaded Adrenaline Auto-Injector (AAI) into the outer 
thigh and an ambulance must be called [9]. If symptoms do 
not improve in 5-10 minutes a second injection is advised 
[10], [11].  Correct use of the most commonly prescribed AAI 
brands, EpiPen® and Jext®, requires the correct completion of 
four steps: 1) safety cap removal, 2) delivery to the thigh, 3) 
holding in place for 10 seconds and 4) massaging the injection 
site for 10 seconds. Empty needleless AAI trainer devices are 
available for the purpose of practicing injections. 
 
   The management of anaphylaxis requires allergen avoidance 
and emergency preparedness [7], [9], [12], [13]. Allergen 
avoidance includes the inspection of food ingredient labeling 
[12], [14], for example, a chocolate bar may have 
precautionary advisory labeling such as “may contain nuts”;  
and awareness of contamination risks, for example, if food is 
cut with a knife that has been in contact with an allergen. 
Emergency preparedness includes knowing how to recognize 
anaphylaxis symptoms, training in the use of AAIs [15] and 
having an emergency allergy action plan [9], [10], [16], [17].  
 
     The contribution of this paper is three-fold: i) it presents 
AllergiSense, a prototype smartphone app and sensing system 
for emergency preparedness in anaphylaxis management; ii) 
provides laboratory evidence, for an injection feedback tool, 
of significantly improved practice injection skills; and iii) 
provides proof-of-concept evidence to support a case for 
future clinical trials implementing the technology with both 
physicians and patients inside and outside the clinic.  
 
     AllergiSense design and evaluation was motivated by the 
fact that the correct use of AAIs is significant in anaphylaxis 
management [18] and because there are widely reported 
failures in the provision of appropriate training and failures in 
AAI injection procedure [19]-[29]. For example, Brown et al. 
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[20] reported that only 15 out of 100 mothers could correctly 
demonstrate AAI use despite a prior demonstration. Arkwright 
and Farragher [30] found that 69% of the parents of food 
allergic children attending a UK clinic were unable to use their 
AAIs, did not have them available or did not know when to 
administer them. In a randomized study with 343 previously-
trained Canadian school staff, Nguyen-Luu et al. [27] found 
that only 26.3% of the participants who had been fully 
informed at recruitment about the AAI assessment could 
demonstrate correct AAI use. And only 15.8% of the 
participants who were not fully informed about the assessment 
could correctly demonstrate AAI use. Physicians have also 
been shown to lack AAI skills [18], [29]. For example, Mehr 
et al. [31] have suggested that insufficient knowledge from 
prescribing physicians was a contributing factor to the failure 
of parents and children activating the device correctly. The 
authors recruited 100 pediatric hospital physicians (including 
residents, registrars and consultants), half of whom had 
already prescribed AAIs. Only 2% of their demonstrated 
injections were assessed as fully correct, improving to 41% 
after they reviewed AAI instructions but still one in five self-
injected their own thumbs. Similarly, Arga et al. [18] found in 
a study with 151 general pediatrics physicians, residents and 
consultants that only thirty-five (23%) were able to 
demonstrate correct AAI use, improving to 74% after training 
and practice. Observing deficiencies on retesting six months 
later, the authors [18] recommended repetition of education. 
     The consensus in the clinical literature is that training 
should be improved and should ensure correct injection 
techniques are used, and that training should be continuous, 
monitored and assessed by allergy specialists so that skills are 
refreshed and maintained [9], [19], [25], [26], [28], [32], [33]. 
     Advances in pervasive and assistive health technology 
research, evident in the expanding literature, have contributed 
toward improved management of other chronic health 
conditions such as diabetes, asthma, cardiovascular diseases 
[34]-[36] and mental illness [37], but anaphylaxis has been 
neglected [38]. A search of online app stores (Android and 
Apple - August 2014) returned nine information-giving 
smartphone anaphylaxis apps and services, most of which 
were produced by support groups [39] and AAI manufacturers 
[40], [41]. For example, there were apps with instructions for 
using a manufacturer’s AAI, apps providing text reminder 
services about AAI expiry dates or apps providing text alerts 
about allergen contamination in the food supply chain. As 
with other healthcare apps, there is lack of reported evaluation 
in the literature [42], [43]. In addition, there are no systems or 
apps providing feedback on injection performance or 
encouraging maintenance of AAI skills. 
 
     We aimed to investigate whether adrenaline injection 
training using AllergiSense to supplement traditional paper 
documents, may provide improved injection training skills and 
better self-efficacy levels in comparison with adrenaline 
injection training using paper documents alone. The following 
section presents the design of AllergiSense and then section III 
describes its implementation. Section IV explains how 
AllergiSense injection feedback tools were evaluated and 
section V presents the results of the evaluation. Finally section 
VI provides a discussion of results and section VII outlines the 
conclusions of this paper.  
II.      ALLERGISENSE DESIGN  
A.  Design based on self-efficacy theory 
     The AllergiSense design and its evaluation were grounded 
in self-efficacy theory [44].  Self-efficacy theory is central to 
social cognitive theory. It refers to one’s belief in one’s ability 
and it is a major predictor of self-management outcomes and a 
contributor to performance ibid.  
     Self-efficacy is modified by four information sources [44]: 
Enactive experience - experiencing attainment through practice 
and mastery. Vicarious experience - modeling others. Social 
persuasion - encouragement or discouragement from others. 
Physiological states - interpretation of one’s physiological 
responses as indicators of personal competency. 
     Health-promotion interventions based on social and 
behavioral science theories are more effective than those 
without a theoretical base [45]. Though technology 
evaluations may incorporate assessments of self-efficacy, the 
majority of reported studies are not theoretically based on 
such. In a review of mobile devices for healthcare and 
behavioral change, Free et al. [35] observed only seven of 
twenty-six (26.9%) behavioral change studies reported using 
behavioral change theories to underpin their intervention.   
      
B.  Design methodology 
     The ambition of AllergiSense was to support anaphylaxis 
self-management. The design and evaluation was informed by 
technological prototyping [38], [46], participatory design [47] 
and a multi-stage methodology enriched with embedded self-
efficacy sources. 
     The motivation for incorporating participatory design was 
to evolve an improved design from a deeper understanding of 
anaphylaxis management needs and from different 
perspectives of users and stakeholders. The participatory 
design process, shown in Fig. 1, comprised two workshop 
events with expert clinical participants, caregivers for 
individuals at risk of anaphylaxis, an adult with a history of 
anaphylaxis, and system designers. Participants identified two 
main anaphylaxis management contexts: emergency and 
everyday life. They also identified specific management needs 
 
 
Fig. 1. Participatory design methodology embedded with self-efficacy 
components. 
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including help to educate others, support for AAI use and AAI 
management, and help with emergency situations. Participants 
created paper interface prototypes of tools to support these 
needs using the PICTIVE (Plastic Interface for Collaborative 
Technology Initiatives through Video Exploration) 
participatory design approach [47]. 
 
 
Fig. 2. AllergiSense mock-up prototype screenshots: a) Example of interfaces 
choices presented to participants: Button vs icon menu styles; b) Examples of 
participant suggestions (relocation of cancel button to avoid pressing it by 
mistake; ticks and crosses over emoticons for injection feedback). 
 
    In addition to tools explicitly suggested in the participatory 
design process, an AAI injection training tool was created as a 
vehicle to increase self-efficacy: encouraging mastery (via 
performance support) and providing persuasion (via 
feedback). A simplified injection force-sensing tool had been 
developed in earlier technology prototyping [38]. The tool was 
enhanced and a new user interface was included in mock-ups 
presented at the participatory design session 2 for participant 
feedback. Interfaces for the full set of tools were mocked-up 
using Balsamiq® software for higher fidelity user interface 
prototyping. Fig. 2. shows a) an example of one of the 
interface design choices presented to participants and b) shows 
examples of participant preferences. As well as the bold and 
strictly consistent use of function coloring (red for emergency 
and green for everyday function), these examples demonstrate 
ways in which AllergiSense design considerations varied from 
those of a generic app. With effective and error-free use 
identified as a top priority; clarity, simplicity and consistency 
were essential to the interface design. For example, of the 
choices shown in Fig. 2a, participants preferred the simple 
button menu style with sympathetic coloring. In Fig. 2b, 
participant annotations show a preference for the emergency 
button (and cancel emergency button) at the top of the screen 
which they said would improve visibility and better avoid 
pressing it by mistake, and, as shown, ticks and crosses were 
preferred for clarity in the injection training feedback tool. 
III.  ALLERGISENSE IMPLEMENTATION 
A.  AllergiSense mobile application tools 
     The AllergiSense design and the information content were 
subject to clinical inspection prior to the production of the 
final prototype used in the evaluation. AllergiSense was 
implemented in an Android Smartphone. Example screenshots 
are shown in Fig. 3. For everyday life, the AllergiSense tools 
include a list of AAI expiry dates with reminders, videos about 
anaphylaxis and symptoms, a step-by-step trainer tool 
showing how to use an EpiPen® AAI, and the AAI trainer tool 
to provide feedback on the correctness of sensed injection 
steps. The AAI expiry date tool (Fig. 3d) requires users to 
initially ‘register’ the serial number ID and expiry date of each 
of their AAIs. The shelf life of EpiPen® and Jext® AAIs is 18 
months. In part, this tool is equivalent to the alert services 
provided by these manufacturers which send email or SMS 
text messages at four months and two months prior to expiry 
and again one day after expiry. But, as suggested by our 
design participants, this AllergiSense tool has additional 
functionality, for example, it stores the usual location of each 
AAI and provides the number of days before each expires. 
Green, yellow and red emoticons also summarize the AAI 
expiry states, namely, "OK", "nearing expiry" and "expired", 
respectively. 
     For emergency scenarios, AllergiSense tools include a 
single-screen emergency 'what to do' list and step-by-step AAI 
instructions. In addition, AllergiSense emergency messaging 
tools can send text messages to predefined numbers 
identifying the user’s GPS location, and emergency services 
can be contacted with the touch of a button. 
B.  AllergiSense sensing unit     
     Fig. 4 shows the sensing unit mounted on an AAI trainer 
device. It was encased in a slim plastic cover and comprised 
an Arduino "Pro mini" microcontroller, a 3-axis 
accelerometer, a push button sensor (to detect removal of the 
safety cap), a Bluetooth™ transceiver and a coin cell battery.  
     The role of the sensing unit was to detect removal of the 
safety cap and to collect acceleration data. The accelerometer 
sensor unit was configured to sample X, Y and Z acceleration 
channels at 70 Hz. This sampling rate was empirically selected 
as sufficiently high for injection sensing fidelity and 
sufficiently sustainable in terms of battery life. All data were 
transmitted to the smartphone using a Serial Port Profile (SPP) 
and used by the injection feedback training tool to determine  
if the safety cap had been removed, if the injector was held the 
right way around, if a 'swing and jab' was performed and if the 
trainer was held in place for 10 seconds.  
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a)      b)      c)            
d)     e)    f)      
g)     h)   i)  
 
Fig. 3.  AllergiSense screenshots: a) Initial screen; b) Emergency and everyday life menu buttons; c) Everyday life tools menu; d) AAI expiry dates list;        
e) Information menu; f) Injection step-by-step instructions;  g) Injection training questions; h) Injection feedback screen (provided after pressing the 
button 'Get score' in 3g); i) Emergency tools. 
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     The removal of the safety cap was detected directly by the 
sensor underneath the cap. Two action classes were used to 
identify the injection steps: “swinging and jabbing” (when 
delivering the injection) and “still” (when holding the trainer 
injector in place). A third class, “moving”, was defined as any 
other action. These classes were defined by accelerometer 
training data from twelve correctly performed injections 
provided by an allergy clinician. All the clinician’s injections 
were performed with the right hand (the clinician’s dominant 
hand). Six were performed while standing and six while 
sitting. 
  
     Classification was performed using a J48 binary decision 
tree using accelerometer data features that included the mean, 
standard deviation, maximum and minimum values, difference 
between the maximum and minimum values, and the average 
distance from the mean. J48 is an open source Java 
implementation of the C4.5 decision tree algorithm in the 
WEKA data mining application. This algorithm was chosen 
for ease of implementation and its robust performance in 
testing. A correct injection is identified as a sequence of steps 
in the following order: “moving”, “swinging and jabbing”, 
“still” and “moving”. The results of testing with participant 
data were: “swinging and jabbing”  was classified with an 
accuracy of 81%, precision of 96% and recall of 83%                     
(F-measure = 89%); “still” was classified with an accuracy of 
81%, precision of 83% and recall of 91% (F-measure = 87%). 
C.   AllergiSense injection feedback tool     
 
     The AllergiSense injection feedback tool provides out-of-
six marks for practiced injections as depicted in Fig 3h. The 
tool assesses injection site and massage time via two questions 
with randomly located answers in pull-down menus (shown in 
Fig. 3g), and the other four assessments (cap removed, injector 
the right way around, swing and jab, and held in place for 10 
seconds) are assessed automatically via the data 
communicated from the sensing unit. 
 
     If users provide incorrect responses or perform erroneous 
actions these are marked as incorrect as depicted in Fig. 3h, 
the out-of-six score is deducted accordingly and informative 
recommendations are provided in a subsequent screen if the 
user presses the 'Recommendations' button. The 
recommendation explains how to improve a specific step of 
the injection and encourages another injection training 
attempt.  
IV.  ALLERGISENSE EVALUATION  
     The AllergiSense adrenaline injection training tool was 
evaluated with a three-arm, pre-post (two-week), randomized 
controlled study with sixty-three healthy participants recruited 
from the University of Birmingham, UK.   
 
     The main hypothesis of this evaluation was that using 
AllergiSense (in addition to traditional training using 
information leaflets) would enhance adrenaline injection 
training skills compared to traditional instruction using 
information leaflets alone. The primary aim of the evaluation 
was an assessment of the effect of different training materials 
on practiced adrenaline injection skills.  The secondary aim 
was to evaluate participants’ self-reported AAI self-efficacy, 
workload, system usability, system usefulness, ease-of-use and 
attitudes towards its use. 
   
    The training provided was clinically approved and the 
procedure overseen by an expert clinical collaborator. 
A.  Statistics 
     A Shapiro-Wilk test was used to test if results were 
samples of a normally distributed population (Significance 
level = 0.05) [48]. Parametric t-tests and ANOVA test were 
used on normally distributed results; Friedman's Rank and 
Mann-Whitney (U) tests for results not normally distributed 
and chi-squared test (χ2) for comparing frequencies of data. 
The statistical tests were undertaken using SPSS® version 20.  
B.  Participants 
     Sixty-three student and staff participants aged between 18-
60 were recruited via email invitation from the University of 
Birmingham, UK. All participants reported carrying and using 
mobile phones. Participants were block randomized into three 
groups of twenty-one participants. The groups comprised 
participants with broadly equivalent smartphone experience in 
terms of smartphone usage and number of apps used, and with 
similar average age and gender balance, and all participants 
were right-handed. Individuals known to be at risk of 
anaphylaxis and their caregivers were excluded from the study 
(their recruitment would have required extensive National 
Health Service ethical permissions; future approval for testing 
of new technology with patients would be more likely in the 
event of positive outcomes from testing with healthy 
participants).  
C.  Assessment of performance and administered 
questionnaires 
     The assessment of AAI performance was based on the 
four-step marking scheme used in other studies [19], [29], 
which, in turn, were based on the steps recommended by the 
EpiPen® AAI manufacturer [49] which are: 
 
1. “Remove the blue safety cap. 
2. ’Swing and jab’ the orange tip of the AAI trainer 
against the outer thigh until it 'clicks'.   
3. Hold firmly against the thigh for 10 seconds. 
4. Remove the auto-injector from the thigh. The orange 
tip will extend to cover the needle and massage the 
injection area for 10 seconds.” 
 
 
Fig. 4. AllergiSense sensing unit mounted on an EpiPen® AAI trainer 
device. 
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The AllergiSense system separates step 2 into two by             
i) sensing “swing and jab” and ii) explicitly asking the user to 
select the correct injection site from a randomly ordered list. 
In addition, AllergiSense senses for the injector being held the 
right way around. This means that while AllergiSense assesses 
the four step injection performance, it reports on-screen out of 
six rather than out of four (Fig. 3h).  
 
The performance of all participants’ adrenaline injections 
was evaluated via video observation of the four recommended 
steps. An inter-rated test with an independent researcher was 
carried out with a random sample of injections                        
(Cohen’s Kappa > 0.8). Injection step differences were 
discussed with, and verified by, the independent researcher 
using the recorded video and sensor data from the 
AllergiSense sensing unit. 
 
     Workload and self-reported usability. NASA TLX [50] and 
System Usability Scale (SUS) [51] questionnaires were used 
for evaluation of workload and self-reported usability, 
respectively. NASA TLX quantifies workload component 
levels of mental, physical and temporal demands. The SUS 
questionnaire provides a measure of perceived usability, 
covering aspects of acceptance, need for support, training and 
system complexity [52], [53].  
 
     Self-efficacy. A self-efficacy questionnaire for adrenaline 
injection was created using eleven-point (0: Not at all 
confident – 10: Totally confident) scale responses as 
recommended by Bandura [54]. The questionnaire comprised 
statements relevant to the use of AAIs in training and 
emergencies for participants to rate. For example, “I am 
confident that I can correctly use an auto-injector trainer in a 
practice session.”, “I am confident I can apply the correct 
force when injecting”, “I am confident I can identify the 
correct injection site”, “I am confident I can correctly use an 
auto-injector in an allergic emergency” and “I am confident 
that I would inject correctly in an emergency even if I was 
very anxious”. The selection and phrasing of the questions 
was first reviewed by allergy clinical collaborators and 
assessed by eighteen allergy specialists.  
 
Usefulness, ease-of-use and attitudes towards use. Self-
reported measures of usefulness, ease of use and willingness 
regarding use were collected from technology acceptance 
questionnaires [55]. 
 
D.  Materials 
     Subsequent to clinically approved training (i.e., allergy 
specialist’s videos about anaphylaxis and EpiPen® use), 
participants were randomly assigned to one of the three 
following groups. 
    
     Paper (traditional care information with paper leaflets 
documentation). Participants in all groups received a paper 
copy of the EpiPen® AAI instruction leaflet (the instructions 
for use provided in the EpiPen® AAI patient information). 
This document provides information about injector use and 
step-by-step pictures for each of the four injection steps. 
Participants in the paper-only (control) group received only 
this information. Participants in the other groups had this 
material supplemented with AllergiSense materials as 
described below.  
 
     AllergiSense without feedback. Participants in this group 
received the AllergiSense smartphone system without the 
injection practice feedback functionality, i.e., AllergiSense 
without the out-of-six injection practice feedback. Thus 
participants with AllergiSense without feedback were 
provided with the paper instructions (the same as the control 
paper group) supplemented with smartphone video (an 
instructional Epipen® AAI video produced by the 
manufacturer and available online on the EpiPen® AAI 
website) and an AAI step-by step instruction tool (text and 
pictures as per paper steps depicted in Fig. 3f).  
 
AllergiSense. This was the complete AllergiSense 
smartphone system using the sensing unit connected to the 
AllergiSense smartphone and providing out-of-six injection 
feedback. Thus, participants in this group were provided paper 
instructions (the same as the control paper group) 
supplemented with smartphone AAI step-by-step instructions 
(Fig. 3f) and an AAI usage video (the same as the 
AllergiSense without feedback) and the mark out-of-six 
injection feedback (Fig. 3h). 
 
All the three groups used the same AllergiSense sensing 
unit depicted in Fig. 4. All sensor data for all participants in all 
groups was logged and recorded during the experimental 
sessions. Data from the paper-only group and the AllergiSense 
without feedback group were recorded via HyperTerminal for 
research records. While the data of the AllergiSense group 
were recorded in the smartphone. Participants in the 
AllergiSense group were the only people that received 
feedback about their training injections.  
 
E.  Experimental procedure 
     The experiment comprised two sessions, two weeks apart. 
In session one, participants were randomly allocated to one of 
the three groups. All participants received the same clinically 
approved training with videos of an allergy specialist using an 
EpiPen® AAI trainer. Participants were then asked to 
demonstrate an injection of adrenaline with the trainer device 
(Demonstration 1), and were then provided with one of three 
different training materials described earlier: paper-only, 
AllergiSense without feedback or AllergiSense. Participants 
were then required to practice three injections using their 
allocated training materials before completing a demonstration 
injection (Demonstration 2). In session two, two weeks later, 
participants were recalled to demonstrate their injection skills 
(Demonstration 3) then practice three injections using their 
allocated training material before completing a final 
demonstration injection (Demonstration 4). 
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     Only the participants in the AllergiSense group received 
feedback on their injection performance (from the injection 
feedback training tool - Fig. 3h). All other participants 
received no feedback on their injections until they were 
provided with an account during the experimental debrief at 
the end of session two. None of the participants reported extra 
training between sessions. 
V.  RESULTS 
     Table I shows the number of participants in each group that 
correctly completed the four injection steps. Only 28.6% of 
the paper-only group correctly completed all four injection 
steps in their final demonstration vs. 66.7% for AllergiSense 
without feedback and 90.5% for AllergiSense. Although more 
people in the AllergiSense group performed all steps correctly 
after the initial training (i.e., in Demonstration 1), there were 
no significant differences between groups: 5 vs 4 (p = 0.707), 
5 vs 7 (p = 0.495) and 4 vs 7 (p = 0.242). Similarly, after 
training in session 1 (i.e., in Demonstration 2) although more 
people in the AllergiSense group correctly completed all the 
steps, there were no significant differences between the 
groups: 5 vs 9 (p = 0.19), 5 vs 10 (p = 0.107) and 9 vs 10 
(p = 0.757). However, after training in session 2 (i.e., in 
Demonstration 4) significantly more people in the 
AllergiSense and AllergiSense without feedback groups 
completed the four steps correctly compared to the control 
(paper-only) group: 6 vs 19 (p < 0.001) and 6 vs 14 
(p = 0.013) respectively, while the difference between 
AllergiSense without feedback and AllergiSense showed a 
trend towards significance: 14 vs 19 (p = 0.060). The 
AllergiSense group improved significantly after training in 
session 2, from 9 to 19 of 21 participants injecting without 
error (p = 0.013), and the AllergiSense without feedback 
group showed a trend towards significance: from 8 to 14 of 21 
participants injecting without error (p = 0.064). 
 
TABLE I 
PRIMARY OUTCOME: NUMBER OF PEOPLE CORRECTLY COMPLETING THE FOUR 
INJECTION STEPS 
Group Session 1 Session 2 
 
Demonstration 
1                          
(after 
watching 
clinical video) 
Demonstration 
2                         
(after training) 
Demonstration 
3                            
(after two 
weeks) 
Demonstration 
4                         
(after  
training) 
1.Paper-only 
5 5 8 6 
(23.8 %) (23.8 %) (38.1 %) (28.6 %) 
2.AllergiSense 
without 
feedback 
4 9 8 14 
(19.0 %) (42.9 %) (38.1 %) (66.7 %) 
3.AllergiSense 
7 10 9 19 
(33.3 %) (47.6 %) (42.9 %) (90.5 %) 
     
     In contrast, the paper-only group actually deteriorated in 
session 2: from 8 to 6 of 21 participants injecting correctly, 
and across the four demonstrations there was no significant 
change in this group’s injection ability despite the training 
opportunities (p > 0.05). 
      
     For the two AllergiSense groups the number of errors made 
decreased with training. The total number of injection errors 
from all four demonstrations of the three groups was 225 
(from a theoretical maximum of 1008 errors = 63[participants] 
× 4[possible errors] × 4[demonstrations]). Only 3.1% of all 
errors involved a failure to remove the safety cap and all of 
these occurred in Demonstration 1. Not massaging the 
injection site for 10 seconds comprised 52.9% of all errors, not 
injecting with sufficient force comprised 24.9% and not 
holding the AAI trainer in place for 10 seconds comprised the 
remaining 19.1% of all errors.  
 
     In Demonstration 2 more participants in the paper-only 
group injected with sufficient force in comparison with the 
AllergiSense groups, but the difference was not significant             
(p > 0.05). However, at the end of the study (Demonstration 4) 
both AllergiSense groups made significantly less errors in this 
step than the paper-only group. More participants in both 
AllergiSense groups held the AAI trainer in place for 10 
seconds in all four of their demonstrations, compared with the 
paper-only group. After training with their allocated material, 
in Demonstration 2 and Demonstration 4, more people in both 
AllergiSense groups massaged the injection site for 10 
seconds and made significantly less errors in this step at the 
end of the two-week study in comparison with the paper-only 
group. 
TABLE II  
SECONDARY OUTCOMES: SELF-EFFICACY, USEFULNESS, EASE-OF-USE, 
ATTITUDES TOWARDS USE, SYSTEM USABILITY AND WORKLOAD 
  Group 1 
 
Paper-only 
Group 2 
AllergiSense 
without 
feedback 
Group 3 
 
AllergiSense 
Self-efficacy after 
Demonstration 1 
(session 1) 
Average 
score 
7.5 7.6 7.1 
Standard 
deviation 
1.4 1.2 1.4 
Self-efficacy after 
Demonstration 2 
(session 1) 
Average 
score 
8.5 8.6 8.5 
Standard 
deviation 
1.2 1.0 0.9 
Self-efficacy after 
Demonstration 3 
(session 2) 
Average 
score 
8.5 8.7 8.4 
Standard 
deviation 
1.4 1.1 1.0 
Usefulness 
Average 
score 
5.1 6.1 6.2 
Standard 
deviation 
1.5 0.6 1.0 
Ease-of-use 
Average 
score 
4.7 6.2 6.0 
Standard 
deviation 
1.5 0.6 1.0 
Attitudes towards 
use 
Average 
score 
5.1 6.1 6.1 
Standard 
deviation 
1.1 0.6 0.7 
System Usability 
Scale (SUS) 
Average 
score 
68.5 86.3 82.7 
Standard 
deviation 
14.5 9.0 15.9 
Workload                       
(NASA TLX) 
Average 
score 
34.1 31.9 31.5 
Standard 
deviation 
17.1 13.9 12.2 
 
  Table II shows the questionnaire results for self-efficacy, 
usefulness, ease-of-use, attitudes towards use, system usability 
and workload. Self-efficacy differences within groups were 
seen after training with their allocated material in session 1 
(From Demonstration 1 to Demonstration 2). The self-efficacy 
of the paper-only group increased from 7.5 to 8.5 (p < 0.001), 
the AllergiSense without feedback group increased from 7.6 to 
8.6 (p < 0.001) and the AllergiSense group increased from 7.1 
to 8.5 (p < 0.001). Self-efficacy remained high for the three 
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groups for two weeks, and no significant differences were 
found between the three groups (p > 0.05). 
 
     After using their allocated material in session 1 (after 
Demonstration 2), participants in both the AllergiSense and 
AllergiSense without feedback groups reported significantly 
higher average scores for the usefulness, the ease-of use and in 
the willingness to use their training materials compared to the 
paper-only group as follows. Usefulness: 5.1 (paper) vs 6.1 
(AllergiSense without feedback) (p = 0.012); 5.1 (paper) vs 
6.1 (AllergiSense) (p = 0.001); Ease-of-use: 4.7 (paper) vs 6.2 
(AllergiSense without feedback) (p = 0.001); 4.7 (paper) vs 
6.0 (AllergiSense) (p = 0.005); Willingness towards use: 5.1 
(paper) vs 6.1 (AllergiSense without feedback) (p < 0.001) and 
5.1 (paper) vs 6.1 (AllergiSense) (p < 0.001). While there 
were slightly, but not significant differences between 
AllergiSense and AllergiSense without feedback in the levels 
of usefulness, ease-of-use, attitudes towards use and SUS 
scores. 
 
     In addition, both AllergiSense groups reported significantly 
higher system usability scores (SUS), after Demonstration 2, 
than the paper-only group: 68.5 (paper) vs 86.3 (AllergiSense 
without feedback) (p < 0.001); 68.5 (paper) vs 82.7 
(AllergiSense) (p = 0.001). While the workload, reported after 
Demonstration 4, was not significantly different between 
groups (p = 0.991).  
VI.  DISCUSSION OF RESULTS   
     While the results of small studies should, necessarily, be 
interpreted cautiously, the results presented here provide a 
measure of evidence toward the hypothesis that smartphone 
tools supplementing traditional instruction paper leaflets could 
improve adrenaline injection training skills.  
 
    The improved results for AllergiSense could be a 
consequence of improved training from the explicit and 
purposeful reinforcement of self-efficacy via mastery, 
vicarious and social experiences embedded within videos, 
step-by-step instructions and visual feedback. Where, in 
contrast, paper instructions provide only limited modeling 
opportunities from text and pictures. There was no significant 
improvement in the performance of the paper-only group 
throughout the study. 
 
    The results appear to support other reports in the literature 
[19]-[29] regarding the inadequacy of the current approach to 
adrenaline injection education (i.e., expert explanation and 
AAI demonstration). Current instruction, where the use of 
AAIs is just demonstrated does not include provision for 
feedback, nor encouragement nor support of continuous 
practice. This was observed after Demonstration 1 (after the 
clinically-approved training) when, at best, only one third of 
people in the three groups could correctly complete all four 
steps of the injection (23.8%, 19% and 33.3% for control, 
AllergiSense without feedback and AllergiSense, 
respectively). These very low results concur with other 
extremely poor findings reported in the literature.   
 
   One interesting and unexpected result was the significant 
increase in self-efficacy in the paper-only group after first use 
of their material for training (after Demonstration 2). This 
increase was less than the increase for the AllergiSense groups 
but not significantly so. The paper-only group retained their 
increased self-efficacy throughout the study despite the lack of 
any significant improvement in their performance. This was 
exemplified at the end of session 2 by one paper-only 
participant who had made no correct injection demonstrations 
at all, but expressed surprise for each when informed of the 
results. Bandura [56] has reported that improved self-efficacy 
in the absence of improved performance indicates a problem 
in the system. Perhaps then, the experiment revealed 
something of the problem with the current system, i.e., that in 
the absence of monitoring and feedback people have elevated 
self-efficacy based on incorrect assumptions about their 
mastery skills. This could have several consequences, not least 
the lack of motivation for continuous practice. 
      
     Secondary outcome results showed that participants 
reported no significant differences in workload for the three 
different training materials. Interestingly, compared to the 
paper-only group both AllergiSense groups scored 
significantly better for usefulness and ease-of-use of their 
materials and also reported significantly more willingness 
towards use. Additionally, average self-reported usability 
scores (SUS) for both AllergiSense groups were very positive. 
The paper-only participants reported, according to Bangor                
et al.'s adjective scale [57, p. 592], a marginally acceptable 
SUS score of 68.45 (between OK and good), while the SUS 
score for AllergiSense without feedback was 86.31 and was 
82.74 for AllergiSense (both between good and excellent). 
Although the AllergiSense without feedback group reported 
slightly better levels of ease-of-use and SUS scores, and that 
the AllergiSense group reported slightly better levels of 
usefulness and workload, they were not significantly different. 
These results may be an indication that the use of the full 
AllergiSense system (smartphone and sensing unit) did not 
have a substantial impact on self-reported usability measures, 
despite the AllergiSense group carried out more elaborated 
training tasks. 
 
     Results showed that adrenaline injection self-efficacy 
improved after the first training session and then was not 
significantly different two weeks later. Perhaps if participants 
had been recalled six weeks or six months later these self-
efficacy results might be substantially different. Further work 
involving longer-term studies is recommended to investigate 
how self-efficacy and adrenaline injection skills attenuate over 
time and how these are impacted by the training materials 
used. 
 
     This research was limited to short-term evaluations with 
healthy participants. Thus, in every aspect of the work 
presented here there is scope for further contribution. Children 
are most affected by anaphylaxis and the most common 
allergen, peanuts, is not generally outgrown. This new 
generation will need support in the management of their 
anaphylaxis. We hope that the results presented here will 
encourage further technology research and development in 
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support of anaphylaxis management. For example, further 
work is also needed to populate solutions with content and 
define tools aimed at supporting symptom recognition and 
allergen avoidance. Further work could also consider the 
issues of responsibility for the support and maintenance of the 
technology and the information contained within it. In 
addition, further work is needed for the creation and validation 
of self-efficacy questionnaires for anaphylaxis management 
and adrenaline injection and, importantly, much further work 
is needed for evaluation of tools in longitudinal studies with 
patients in and outside the clinic.  
 
VII.  CONCLUSIONS 
     This paper provided experimental evidence supporting the 
potential of smartphone tools and wireless sensors to 
significantly improve AAI training skills, usefully supplement 
traditional care paper information leaflets and positively 
influence injection training performance and user’s self-
efficacy. The study was limited to a randomized, controlled, 
pre-post intervention with healthy participants simulating 
adrenaline injections with an AAI trainer, but still the results 
provided valuable insights and proof-of-concept evidence to 
support a case for future clinical trials implementing the 
technology with both physicians and patients.  
 
     It was noted that participants in the control group, trained 
with traditional care paper information leaflets alone, did not 
improve their AAI performance and made persistent errors in 
administration of the AAI throughout training practice.  
Notwithstanding the poor AAI skills exhibited by the paper-
only group, the results revealed that their levels of self-
efficacy increased, despite being wholly incompatible with 
their actual AAI skills. Whilst it is important to be cautious in 
the interpretation of these data given the limited participant 
numbers, this finding was interesting and unexpected. It may 
provide an insight into deficits in AAI use. Incorrect 
assumptions behind inappropriately elevated self-efficacy 
could be a consequence of the lack of AAI training monitoring 
and feedback and suggests that it is difficult to identify one’s 
own errors and assess one’s own competence. This could have 
several consequences, not least complacency regarding AAI 
training and a lack of motivation for continuous practice. 
 
     The injection sensing implemented in AllergiSense 
performed robustly throughout all evaluations presented here. 
However, in a subsequent qualitative evaluation study in 
which AllergiSense was provided to expert allergy physicians 
and nurses, further improvements were identified. For 
example, the expansion of the training data to include different 
injection scenarios, such as injecting while lying down. 
Improved sensing in realistic scenarios could also be useful in 
prototyping new “smart” AAI designs with emergency AAI 
sensing capability. Further research in support of anaphylaxis 
management may have positive implications since people with 
anaphylaxis and their caregivers are motivated more than most 
to learn how to use AAIs, and carry smartphones because they 
may need to make emergency calls, and so the technology 
platform needed for an assistive healthcare solution is already 
available. 
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